Drug intelligence / Profile preview

AD17002-AI

Development stage: Unknown
Lead developer: Advagene
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

AD17002-AI is an intranasal immunotherapy candidate developed by Advagene Biotechnology for the treatment of allergic rhinitis, specifically targeting house dust mite (HDM) sensitivity. The therapy is a combination of the LTh(αK) immune modulation protein—a detoxified heat-labile enterotoxin (LT) adjuvant—and HDM allergen. It is designed to modulate mucosal immune responses and induce type I interferon to achieve allergen-specific immunomodulation. Administered as a nasal spray, AD17002-AI has completed Phase 1/2 clinical trials, where it was evaluated for safety, tolerability, and potential efficacy in subjects with HDM-induced allergic rhinitis.

Other names: LT-Allergy

Targets

IFNE (Interferon epsilon)

Beyond the preview

Go deeper on AD17002-AI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD17002-AI.

Explore the full profile